Literature DB >> 29765973

Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient.

Yuval Ramot1, Abraham Zlotogorski1.   

Abstract

While most alopecia areata (AA) cases resolve spontaneously, the more severe types of AA, alopecia totalis (AT) and alopecia universalis (AU), can be highly resistant to therapy. We report on a 33-year-old ultraorthodox Jewish man with an 11-year history of AA that resulted in complete loss of the scalp and body hair 7 years ago. Previous treatments with intralesional and systemic corticosteroids had only partial and temporary effects. The patient was treated with ruxolitinib, 20 mg twice daily, resulting in complete growth of the beard after 4 months of treatment. The beard has a special significance for ultraorthodox Jews, and loss of the beard hair can have marked social and psychological consequences in AA patients. The Janus kinase (JAK) inhibitors have recently emerged as an effective treatment modality in AA, including the more severe forms, such as AT or AU. This report highlights the beneficial effects of the JAK inhibitors, especially in populations where the hair has a special importance due to cultural and religious backgrounds.

Entities:  

Keywords:  Alopecia; Alopecia areata; Hair; Janus kinase inhibitors; Ruxolitinib

Year:  2017        PMID: 29765973      PMCID: PMC5939711          DOI: 10.1159/000479722

Source DB:  PubMed          Journal:  Skin Appendage Disord        ISSN: 2296-9160


  18 in total

Review 1.  A novel therapeutic paradigm for patients with extensive alopecia areata.

Authors:  Yael Renert-Yuval; Emma Guttman-Yassky
Journal:  Expert Opin Biol Ther       Date:  2016-05-30       Impact factor: 4.388

2.  Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.

Authors:  Lucy Y Liu; Brittany G Craiglow; Feng Dai; Brett A King
Journal:  J Am Acad Dermatol       Date:  2016-11-02       Impact factor: 11.527

3.  Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring.

Authors:  Amy Vandiver; Nicholas Girardi; Jihad Alhariri; Luis A Garza
Journal:  Int J Dermatol       Date:  2017-03-21       Impact factor: 2.736

Review 4.  Alopecia Areata of the Beard: A Review of the Literature.

Authors:  Jessica Cervantes; Raymond M Fertig; Austin Maddy; Antonella Tosti
Journal:  Am J Clin Dermatol       Date:  2017-12       Impact factor: 7.403

5.  Importance of Group Therapeutic Support for Family Members of Children with Alopecia Areata: A Cross-Sectional Survey Study.

Authors:  Kelly A Aschenbeck; Sarah L McFarland; Maria K Hordinsky; Bruce R Lindgren; Ronda S Farah
Journal:  Pediatr Dermatol       Date:  2017-05-16       Impact factor: 1.588

6.  Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.

Authors:  Milène Kennedy Crispin; Justin M Ko; Brittany G Craiglow; Shufeng Li; Gautam Shankar; Jennifer R Urban; James C Chen; Jane E Cerise; Ali Jabbari; Mårten Cg Winge; M Peter Marinkovich; Angela M Christiano; Anthony E Oro; Brett A King
Journal:  JCI Insight       Date:  2016-09-22

Review 7.  Beard alopecia areata: a multicentre review of 55 patients.

Authors:  D Saceda-Corralo; R Grimalt; P Fernández-Crehuet; A Clemente; C Bernárdez; M J García-Hernandez; S Arias-Santiago; A R Rodrigues-Barata; A Rodríguez-Pichardo; E García-Lora; P Jaén; F M Camacho; S Vañó-Galván
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-09-12       Impact factor: 6.166

8.  Treatment of severe alopecia areata with intralesional steroid injections.

Authors:  Kyung Hee Chang; Salinee Rojhirunsakool; Lynne J Goldberg
Journal:  J Drugs Dermatol       Date:  2009-10       Impact factor: 2.114

9.  Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989.

Authors:  K H Safavi; S A Muller; V J Suman; A N Moshell; L J Melton
Journal:  Mayo Clin Proc       Date:  1995-07       Impact factor: 7.616

10.  Quality of life in alopecia areata: a case-control study.

Authors:  Taciana Rocha de Hollanda; Celso Tavares Sodré; Marco Antonio Brasil; Marcia Ramos-E-Silva
Journal:  Int J Trichology       Date:  2014-01
View more
  4 in total

Review 1.  [Janus kinase inhibitors for the treatment of alopecia areata].

Authors:  Inbar Kobal; Yuval Ramot
Journal:  Hautarzt       Date:  2022-04-28       Impact factor: 0.751

2.  A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata.

Authors:  Daniela Mikhaylov; Jacob W Glickman; Ester Del Duca; John Nia; Peter Hashim; Giselle K Singer; Alba L Posligua; Aleksandra G Florek; Erin Ibler; Erika L Hagstrom; Yeriel Estrada; Stephanie M Rangel; Maria Colavincenzo; Amy S Paller; Emma Guttman-Yassky
Journal:  Arch Dermatol Res       Date:  2022-03-01       Impact factor: 3.017

Review 3.  Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata.

Authors:  Ana M Montilla; Francisco Gómez-García; Pedro J Gómez-Arias; Jesús Gay-Mimbrera; Jorge Hernández-Parada; Beatriz Isla-Tejera; Juan Ruano
Journal:  Dermatol Ther (Heidelb)       Date:  2019-10-13

Review 4.  Role of janus kinase inhibitors in the treatment of alopecia areata.

Authors:  Korn Triyangkulsri; Poonkiat Suchonwanit
Journal:  Drug Des Devel Ther       Date:  2018-07-27       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.